Vanda Pharmaceuticals
VNDA
137 hedge funds and large institutions have $711M invested in Vanda Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 40 reducing their positions, and 15 closing their positions.
460% more call options, than puts
Call options by funds: $6.47M | Put options by funds: $1.16M
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
28% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 40
12% more capital invested
Capital invested by funds: $633M → $711M (+$78M)
3% more funds holding
Funds holding: 133 → 137 (+4)
1.33% more ownership
Funds ownership: 87.22% → 88.55% (+1.3%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$22M |
| 2 |
Millennium Management
New York
|
+$16.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$7.09M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.55M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$5.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$30.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$29M |
| 3 |
AC
Armistice Capital
New York
|
-$8.9M |
| 4 |
NC
Nexthera Capital
New York
|
-$7.53M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$6.44M |
VNDA Hedge Fund Activity: Q3 2017 in Review
137 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2017, worth a combined $711M — up 12% from $633M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VNDA positions and 15 closed out — a net gain of 5 holders — while 51 added to existing stakes and 40 trimmed.
The largest buyer was Rothschild & Co Asset Management US, opening a new position worth an estimated $22M. The largest seller was Point72 Asset Management, cutting an estimated $30.8M.
- 137 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2017, up from 133 in Q2 2017.
- Funds reported $711M of Vanda Pharmaceuticals stock for Q3 2017, up 12% quarter-over-quarter.
- 20 funds opened new Vanda Pharmaceuticals positions in Q3 2017 and 15 closed out, a net change of +5 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2017 was Rothschild & Co Asset Management US, an estimated $22M added.
- The largest Vanda Pharmaceuticals seller in Q3 2017 was Point72 Asset Management, an estimated $30.8M sold.
Based on aggregated 13F filings for Q3 2017.